Orencia (abatacept) — HCPCS J0129

Orencia IV vs. Orencia ClickJect SC FDA verified May 2026

Same molecule, completely different billing pathway. Confusing the two is a common claim error.

BMS markets abatacept in two distinct presentations. Orencia IV (the 250 mg lyophilized vial) is provider-administered as an infusion and runs through the medical benefit under HCPCS J0129. Orencia ClickJect (autoinjector) and the matching SC prefilled syringe are patient self-administered weekly at 125 mg and run through the pharmacy benefit as a specialty-pharmacy dispense. The SC formulation is NOT billed under J0129 in any setting.

Dosing & unit math FDA label verified May 2026

Adult RA / PsA uses fixed weight-tiered dosing — not mg/kg. Pediatric JIA and aGVHD prevention use mg/kg.

Adult RA and PsA — weight-tiered fixed dose

Orencia IV uses a unique three-tier fixed dose for adult rheumatoid arthritis and active psoriatic arthritis. The tiers correspond exactly to whole-vial multiples of the 250 mg vial — producing zero waste in nearly every case. Schedule: weeks 0, 2, and 4, then every 4 weeks thereafter.

Pediatric polyarticular JIA (ages ≥6 yr)

• 10 mg/kg IV on weeks 0, 2, 4, then every 4 weeks
• Maximum dose: 1,000 mg per administration
• Bill the actual mg administered, rounded up to the next 10 mg increment for J0129 units
• Partial-vial waste possible — bill JW for discarded units on a separate line
• SC formulation also approved for JIA ≥2 yr (pharmacy benefit)

Acute GVHD prevention (HSCT, ≥2 yr)

• 10 mg/kg IV on a defined peri-transplant schedule (day -1, +5, +14, +28)
• Maximum dose: 1,000 mg per administration
• Used in combination with calcineurin inhibitor + methotrexate per the BLA-supporting trial
• Bill J0129 with appropriate Z-code for HSCT and underlying malignancy

Worked example — first-year billing for a 75 kg adult RA patient

Reconstitution (don't skip the silicone-free detail)

Each 250 mg vial is reconstituted with 10 mL sterile water for injection using the manufacturer-supplied silicone-free disposable syringe — silicone in standard syringes can produce translucent particulate. Resulting concentration is 25 mg/mL. Total dose volume is then withdrawn and added to a 100 mL infusion bag of 0.9% NaCl (volume-matched: remove an equal volume from the bag first). Infuse over 30 minutes through a 0.2–1.2 micron low-protein-binding inline filter. Stable 24 hr refrigerated; use immediately if practical.

No premedication routinely required

Unlike the anti-CD20 monoclonal antibodies (Ocrevus, Briumvi, Rituxan), Orencia does NOT require routine pre-infusion methylprednisolone or antihistamine. Manage infusion / hypersensitivity reactions per FDA label if they occur.

NDC reference FDA NDC Directory verified May 2026

Administration codes CPT verified May 2026

Abatacept is a non-cytotoxic biologic. Therapeutic IV codes apply — not chemotherapy administration.

Modifiers CMS verified May 2026

JZ — required on virtually every adult RA / PsA claim

Effective July 1, 2023, CMS requires the JZ modifier on all single-dose container claims when no drug is discarded. Because Orencia's adult weight-tiered doses (500 / 750 / 1,000 mg) align exactly to whole-vial multiples of the 250 mg single-dose vial — 2, 3, or 4 vials respectively — JZ applies to virtually every adult RA and PsA claim with zero waste.

JW — pediatric JIA and aGVHD prevention only

JW reports the discarded portion of a single-dose vial. For Orencia, JW only applies to the weight-based mg/kg pediatric JIA dose and the 10 mg/kg aGVHD prevention dose where the calculated dose does not divide evenly into 250 mg vials. Example: a 22 kg JIA patient receiving 220 mg uses one 250 mg vial and discards 30 mg — bill JW with 3 units of waste on a separate claim line, alongside the JZ-style line for the 22 units administered (220 mg ÷ 10). One of JZ or JW must be on every J0129 claim.

Modifier 25 — same-day E/M

Use modifier 25 on the E/M code when a significant, separately identifiable evaluation and management service is performed on the same day as the infusion (e.g., active flare assessment, dose-tier change review). Routine pre-infusion clinical assessment and vital signs are bundled.

340B modifiers (JG, TB)

For 340B-acquired Orencia, follow your MAC's current 340B modifier policy. Most MACs require JG on Part B claims for 340B drugs at hospital outpatient sites; TB on rural / sole community hospital claims. Verify per MAC at billing time.

ICD-10-CM by indication FY2026 verified May 2026

Indication coverage spans rheumatology and stem-cell transplant. Use the most specific code supported by the chart.

Site of care & place of service Verified May 2026

UnitedHealthcare, Aetna, and most major BCBS plans run aggressive site-of-care UM for biologic infusions. For Orencia specifically, payers often require either (a) office / AIC administration after the loading period or (b) transition to SC self-administration once the patient is stable on therapy.

Claim form field mapping BMS Access Support 2026

From BMS Access Support — Orencia HCP coding & coverage page.

Payer policy snapshot Reviewed May 2026

Most major commercial payers require step therapy from a TNF inhibitor for adult RA before approving Orencia.

Concomitant therapy expectations

• Methotrexate: Most payers expect concurrent MTX for adult RA unless contraindicated or not tolerated. Document the rationale for monotherapy if applicable.
• Avoid stacking biologics / JAK inhibitors: Concurrent use with TNF inhibitors, anakinra, JAK inhibitors (Xeljanz, Rinvoq), or other biologic DMARDs is contraindicated and will cause PA denial.
• Live vaccines: Avoid during therapy and for 3 months after discontinuation. Document immunization status pre-initiation.

Step therapy & switching

For adult RA, the most common PA pathway is documented inadequate response or intolerance to at least one TNF inhibitor (Humira / Remicade / Enbrel). For PsA the same step often applies. Switching from one biologic to Orencia generally requires documentation of the prior agent, duration of trial, and reason for failure (efficacy, safety, or AE).

Medicare reimbursement CMS Q2 2026 (live)

Quarterly ASP from CMS Part B Drug Pricing File. Refreshes automatically each quarter.

Coverage

No NCD specific to abatacept. Coverage falls under MAC LCDs for biologic DMARDs and autoimmune therapies, plus the generic drug-coverage framework. All MACs cover J0129 for FDA-approved on-label indications with appropriate ICD-10 and TB screening documentation.

Code history

• J0129 — permanent code in continuous use since shortly after FDA approval (December 2005). Descriptor: "Injection, abatacept, 10 mg."
• Pre-permanent-code period billed under unclassified J3490 with NDC documentation.

Patient assistance — BMS Access Support BMS verified May 2026

• BMS Access Support: 1-800-861-0048 — benefits investigation, prior authorization assistance, appeal support, alternate funding research
• Orencia Co-Pay Assistance Program: commercially-insured patients pay as little as $5 per month, up to $20,000 per calendar year; excludes Medicare, Medicaid, and other federal program patients
• BMS Patient Assistance Foundation: free product for uninsured / underinsured patients meeting income requirements (administered through the BMS Patient Assistance Program, Inc., a 501(c)(3))
• Foundations for Medicare patients: refer to PAN Foundation, HealthWell Foundation, Good Days, Patient Advocate Foundation — verify open RA and PsA funds quarterly (funds open and close based on funding cycles)
• Web: orencia.com financial support page · bmsaccesssupport.com

Common denials & how to fix them

Frequently asked questions

What is the HCPCS code for Orencia?

Orencia IV (abatacept) is billed under HCPCS J0129 — "Injection, abatacept, 10 mg." Each 10 mg equals one billable unit, so a 500 mg dose is 50 units, 750 mg is 75 units, and 1,000 mg is 100 units. J0129 has been the permanent code since shortly after Orencia's December 2005 FDA approval. The Orencia ClickJect / SC prefilled syringe is NOT billed under J0129 — it dispenses through specialty pharmacy under the pharmacy benefit.

How do I bill the weight-tiered RA dose?

For adult RA and PsA, Orencia uses a fixed weight-tiered dose: 500 mg (<60 kg) = 50 units of J0129; 750 mg (60–100 kg) = 75 units; 1,000 mg (>100 kg) = 100 units. Each tier matches whole-vial multiples of the 250 mg vial (2, 3, or 4 vials), producing zero waste in nearly every case — bill JZ. Schedule: weeks 0, 2, 4, then every 4 weeks thereafter.

What administration CPT do I use for Orencia?

CPT 96365 — "Intravenous infusion, for therapy/prophylaxis/diagnosis; up to 1 hour." Add 96366 for each additional hour beyond the first. Orencia's standard infusion is 30 minutes, fitting within the 96365 single-hour window. Do NOT bill 96413 / 96415 — abatacept is a non-cytotoxic biologic (CTLA-4-Ig fusion protein), not chemotherapy. Chemo admin codes will trigger payer denials and audit risk.

Do I bill JZ or JW for Orencia?

Bill JZ on virtually every adult RA / PsA claim. The weight-tiered fixed doses (500 / 750 / 1,000 mg) align exactly to whole-vial multiples of the 250 mg single-dose vial — 2, 3, or 4 vials with zero waste. JW only applies to JIA pediatric weight-based dosing (10 mg/kg, max 1,000 mg) and acute GVHD prevention dosing where a partial vial may be discarded. One of JZ or JW must appear on every J0129 claim per the CMS July 2023 single-dose container policy.

What is the Medicare reimbursement for J0129?

For Q2 2026, the Medicare Part B payment limit for J0129 is $44.718 per 10 mg unit (ASP + 6%). The 750 mg (60–100 kg) RA dose reimburses at approximately $3,353.85 per infusion; the 500 mg dose at $2,235.90; and the 1,000 mg dose at $4,471.80. Maintenance schedule of 13 doses per year (every 4 weeks) on a 750 mg dose totals approximately $43,600/year. Sequestration (~2%) reduces actual paid to roughly ASP + 4.3%.

What is the difference between Orencia IV and Orencia ClickJect?

Orencia ClickJect is the subcutaneous prefilled autoinjector (also available as a 125 mg/mL SC prefilled syringe) for self-administration at home. It is NOT billed under HCPCS J0129. Because it is patient-administered, it dispenses through specialty pharmacy under the pharmacy benefit, not the medical benefit. The IV formulation (J0129) is provider-administered (buy-and-bill) and runs through the medical benefit with infusion administration codes. Standard SC dosing is 125 mg weekly. Some payers permit a single IV loading dose followed by SC maintenance — verify per policy.

Is TB screening required before starting Orencia?

Yes. The FDA label requires screening for latent tuberculosis infection before initiating Orencia, and treatment of any positive results before therapy. Document the TB test result (interferon-gamma release assay or tuberculin skin test) in the chart. Hepatitis B serology is also recommended pre-therapy because abatacept may reactivate HBV. Most major payers require evidence of TB screening in the prior authorization submission.

Does Orencia have a Boxed Warning?

No. Orencia carries no FDA Boxed Warning — a notable difference from TNF inhibitors (Humira, Remicade, Enbrel) which all carry boxed warnings for serious infections and malignancy. Orencia's Warnings & Precautions cover: serious infections (including TB), malignancies, infusion-related reactions and hypersensitivity, COPD exacerbations in patients with COPD, and hepatitis B reactivation. Pre-therapy TB screening is mandatory; concomitant biologic DMARDs and JAK inhibitors should be avoided.

Source documents

1. Orencia HCP — Bristol Myers Squibb product site
   Manufacturer product information and HCP coding resources
2. Orencia (abatacept) Prescribing Information — BMS package insert
   FDA-approved label, most recent revision (BLA 125118)
3. DailyMed — ORENCIA (abatacept) label collection
   IV lyophilized vial + SC prefilled syringe + ClickJect autoinjector labels
4. BMS Access Support — Orencia coding & coverage HCP page
   Includes co-pay program, PAP, and benefits investigation services. Phone: 1-800-861-0048
5. CMS — Medicare Part B Drug ASP Pricing File
   Q2 2026 quarterly file, effective April 1 – June 30, 2026
6. SEER CanMED — HCPCS J0129 reference
7. American College of Rheumatology — clinical practice guidelines (RA, JIA, PsA)
   ACR guidelines on biologic DMARD use, including positioning relative to TNF inhibitors
8. UnitedHealthcare — Medical Drug Policy library
   Includes biologic DMARD policy with abatacept-specific PA criteria and step therapy
9. Aetna — Clinical Policy Bulletin library
   CPB on biologic DMARDs, including abatacept and site-of-care UM
10. FDA National Drug Code Directory
    Carton-level NDCs for all three Orencia presentations (IV vial, SC syringe, ClickJect)

About this page

We maintain this page as a living reference. Medicare ASP pricing is bound to our underlying CareCost data layer and refreshes automatically when CMS publishes new quarterly files. Coding and policy content is reviewed at least quarterly and updated whenever a source document changes.

Found an error? Email hello@carecostestimate.com.

Refresh cadence

Reviewer

Change log

• May 2, 2026 — Initial publication. ASP data: Q2 2026 ($44.718 per 10 mg unit). Manufacturer source: BMS Access Support 2026. FDA label: most recent revision (BLA 125118). Indications include adult RA, polyarticular JIA, active PsA, and acute GVHD prevention in HSCT patients ≥2 yr.

Methodology

Every claim on this page is sourced inline. Pricing reflects the current CMS Part B Drug ASP Pricing File. Payer policies are read directly from each payer's published medical / pharmacy policy documents. Indications are verified against the current FDA label revision. We do not paraphrase from billing-software vendor blogs.